Jeffrey Robert Ajer - Mar 15, 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Commercial Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Mar 15, 2023
Transactions value $
-$2,264,255
Form type
4
Date filed
3/17/2023, 09:16 PM
Previous filing
Mar 2, 2023
Next filing
Aug 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +10.1K +12.66% $0.00 90K Mar 15, 2023 Direct F1
transaction BMRN Common Stock Tax liability -$348K -3.97K -4.41% $87.74 86K Mar 15, 2023 Direct
transaction BMRN Common Stock Tax liability -$1.92M -20.5K -23.85% $93.41 65.5K Mar 16, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Award $0 +23.1K $0.00 23.1K Mar 15, 2023 Common Stock 23.1K $87.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted on March 15, 2023. Price not applicable.
F2 Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter.